TY - JOUR
T1 - Combined treatment of graft versus host disease using donor regulatory T cells and ruxolitinib
AU - Rodríguez-Gil, Alfonso
AU - Escamilla-Gómez, Virginia
AU - Nufer, Melanie
AU - Andújar-Sánchez, Félix
AU - Lopes-Ramos, Teresa
AU - Bejarano-García, José Antonio
AU - García-Guerrero, Estefanía
AU - Calderón-Cabrera, Cristina
AU - Caballero-Velázquez, Teresa
AU - García-Calderón, Clara Beatriz
AU - Hernández-Díaz, Paola
AU - Reguera-Ortega, Juan Luis
AU - Rodríguez-Torres, Nancy
AU - Martínez-Cibrián, Nuria
AU - Rodríguez-Barbosa, José Ignacio
AU - Villadiego, Javier
AU - Pérez-Simón, José Antonio
N1 - Publisher Copyright:
© 2022, The Author(s).
PY - 2022/5/19
Y1 - 2022/5/19
N2 - Donor derived regulatory T lymphocytes and the JAK1/2 kinase inhibitor ruxolitinib are currently being evaluated as therapeutic options in the treatment of chronic graft versus host disease (cGvHD). In this work, we aimed to determine if the combined use of both agents can exert a synergistic effect in the treatment of GvHD. For this purpose, we studied the effect of this combination both in vitro and in a GvHD mouse model. Our results show that ruxolitinib favors the ratio of thymic regulatory T cells to conventional T cells in culture, without affecting the suppressive capacity of these Treg. The combination of ruxolitinib with Treg showed a higher efficacy as compared to each single treatment alone in our GvHD mouse model in terms of GvHD incidence, severity and survival without hampering graft versus leukemia effect. This beneficial effect correlated with the detection in the bone marrow of recipient mice of the infused donor allogeneic Treg after the adoptive transfer.
AB - Donor derived regulatory T lymphocytes and the JAK1/2 kinase inhibitor ruxolitinib are currently being evaluated as therapeutic options in the treatment of chronic graft versus host disease (cGvHD). In this work, we aimed to determine if the combined use of both agents can exert a synergistic effect in the treatment of GvHD. For this purpose, we studied the effect of this combination both in vitro and in a GvHD mouse model. Our results show that ruxolitinib favors the ratio of thymic regulatory T cells to conventional T cells in culture, without affecting the suppressive capacity of these Treg. The combination of ruxolitinib with Treg showed a higher efficacy as compared to each single treatment alone in our GvHD mouse model in terms of GvHD incidence, severity and survival without hampering graft versus leukemia effect. This beneficial effect correlated with the detection in the bone marrow of recipient mice of the infused donor allogeneic Treg after the adoptive transfer.
UR - http://www.scopus.com/inward/record.url?scp=85130373574&partnerID=8YFLogxK
UR - https://pubmed.ncbi.nlm.nih.gov/35589917
U2 - 10.1038/s41598-022-12407-x
DO - 10.1038/s41598-022-12407-x
M3 - Article
C2 - 35589917
AN - SCOPUS:85130373574
SN - 2045-2322
VL - 12
JO - Scientific Reports
JF - Scientific Reports
IS - 1
M1 - 8348
ER -